Show simple item record

dc.contributor.authorLamarca, Angelaen
dc.contributor.authorMcCallum, Lynneen
dc.contributor.authorNuttall, Christinaen
dc.contributor.authorBarriuso, Jorgeen
dc.contributor.authorFrizziero, Melissaen
dc.contributor.authorLeon, Rebeccaen
dc.contributor.authorMansoor, Wasen
dc.contributor.authorMcNamara, Mairéad Gen
dc.contributor.authorHubner, Richard Aen
dc.contributor.authorValle, Juan Wen
dc.date.accessioned2017-11-21T21:41:04Z
dc.date.available2017-11-21T21:41:04Z
dc.date.issued2017-09
dc.identifier.citation450P Pancreatic exocrine insufficiency (PEI) in patients (pts) with well-differentiated neuroendocrine tumours (wd-NETs) treated with somatostatin analogues (SSAs): incidence and impact on quality of life. 2017, 28(suppl_5): Ann Oncolen
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.doi10.1093/annonc/mdx368.022
dc.identifier.urihttp://hdl.handle.net/10541/620643
dc.language.isoenen
dc.relation.urlhttp://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx368.022/4108671/450PPancreatic-exocrine-insufficiency-PEI-inen
dc.rightsArchived with thanks to Annals of Oncologyen
dc.title450P Pancreatic exocrine insufficiency (PEI) in patients (pts) with well-differentiated neuroendocrine tumours (wd-NETs) treated with somatostatin analogues (SSAs): incidence and impact on quality of life.en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentMedical Oncology, The Christie NHS Foundation Trust, Manchesteren
dc.identifier.journalAnnals of Oncologyen


This item appears in the following Collection(s)

Show simple item record